^
Association details:
| Biomarker: | TP53 mutation + ATM mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Published date:
09/17/2021
Excerpt:
For patients harboring TP53(+), the top five upregulated genes (ZACNN: ZFHX3, ATM, CDKN2A, NOTCH4, and NTRK3) were selected as predictors for screening responders from non-responders. The results indicated that patients harboring ZACNN(+) received more OS benefits from immunotherapy than those harboring ZACNN(−) [ZACNN(+) vs. ZACNN(−) = undefined vs. 8 months, P < 0.0001]...
DOI:
https://doi.org/10.3389/fimmu.2021.732125
Test:
